Insulet (NASDAQ:PODD) Hits New 12-Month High – What’s Next?

Shares of Insulet Co. (NASDAQ:PODD) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $282.87 and last traded at $280.52, with a volume of 12065 shares changing hands. The stock had previously closed at $280.35.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on PODD shares. Barclays upped their price objective on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Citigroup increased their price objective on Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. BTIG Research boosted their target price on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Morgan Stanley boosted their price objective on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Finally, Sanford C. Bernstein initiated coverage on Insulet in a research note on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $272.81.

Insulet Stock Performance

The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The company has a market capitalization of $19.36 billion, a P/E ratio of 47.26, a price-to-earnings-growth ratio of 3.50 and a beta of 1.22. The firm has a 50 day moving average price of $267.83 and a two-hundred day moving average price of $236.83.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.13. Insulet had a return on equity of 27.98% and a net margin of 21.22%. The firm had revenue of $543.90 million during the quarter, compared to analyst estimates of $518.50 million. During the same period in the prior year, the company posted $0.71 earnings per share. On average, research analysts expect that Insulet Co. will post 3.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Insulet news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the transaction, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Hedge Funds Weigh In On Insulet

Large investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP lifted its holdings in Insulet by 10.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 146,746 shares of the medical instruments supplier’s stock worth $29,618,000 after buying an additional 13,351 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new position in Insulet in the second quarter valued at about $158,000. Sei Investments Co. increased its position in Insulet by 148.6% in the second quarter. Sei Investments Co. now owns 29,289 shares of the medical instruments supplier’s stock worth $5,911,000 after purchasing an additional 17,507 shares during the period. Public Sector Pension Investment Board raised its holdings in Insulet by 73.6% during the 2nd quarter. Public Sector Pension Investment Board now owns 2,699 shares of the medical instruments supplier’s stock worth $545,000 after purchasing an additional 1,144 shares during the last quarter. Finally, MBB Public Markets I LLC acquired a new position in Insulet during the 2nd quarter valued at about $955,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.